Contineum Therapeutics, Inc. (CTNM)
NASDAQ · Healthcare
Contineum Therapeutics, Inc. EBITDA 2023–2024
Contineum Therapeutics, Inc. annual/quarterly ebitda history and growth rate from 2023 to 2024. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Contineum Therapeutics, Inc. annual ebitda for 2024 was -50.6 M, a 411.18% decrease from 2023.
- Contineum Therapeutics, Inc. annual ebitda for 2023 was 16.3 M.
No data available.
Contineum Therapeutics, Inc. EBITDA — FAQ
Contineum Therapeutics, Inc. (CTNM) ebitda over the last 2 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see CTNM's ebitda history?
The chart and table above show Contineum Therapeutics, Inc.'s ebitda by year and by quarter, including the growth rate.